Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Lancet (London, England)|May 28, 1977
Complications of cancer immunotherapy with levamisoleD R Parkinson, P O Cano, L M Jerry, et al.The Laryngoscope|January 23, 1999
Pervasive developmental delay in children presenting as possible hearing lossP T Ho, J L Keller, A L Berg, et al.Cancer Research|December 1, 1992
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapyF M Marincola, D Venzon, D White, et al.Journal of Interferon Research|December 1, 1992
Phase II trials of interferons-alpha and -beta in advanced sarcomasE C Borden, K Kim, L Ryan, et al.Breast Cancer Research and Treatment|October 1, 1990
Nuclear binding of the estrogen receptor: a potential predictor for hormone response in metastatic breast cancerN J Robert, L Martin, C D Taylor, et al.Optics Letters|December 21, 2004
Photonic logic NOR gate based on two symmetric microring resonatorsT A Ibrahim, K Amarnath, L C Kuo, et al.La Clinica Terapeutica|July 29, 2025
Non-Clostridium difficile Bacterial Infection in an Acute Flare of Crohn's Disease: A Case Report and Literature ReviewN T Phan, P T Ho, N P Ma, et al.Journal of the National Cancer Institute|July 18, 1990
High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinomaJ S Abrams, A A Rayner, P H Wiernik, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1986
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant diseaseM B Atkins, J A Gould, M Allegretta, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
HLA associations in the antitumor response against malignant melanomaF M Marincola, P Shamamian, L Rivoltini, et al.Pageof 10